Healthcare Equipment and Supplies
Company Overview of Nobel Biocare Holding AG
Nobel Biocare Holding AG operates in the field of implant-based dental restorations worldwide. It offers dental implants for various indications, bone types, and surgical protocols under the NobelActive, Brånemark System, and NobelReplace brands; high-precision individualized prosthetics and CAD/CAM systems for every indication, from a single tooth to edentulous jaws, on natural teeth and implants under the NobelProcera brand; and machined and TiUnite implants. The company also provides a range of individualized CAD/CAM abutments and a portfolio of prefabricated temporary and final abutments; biomaterials for soft tissue and bone regeneration under the creos brand; and removable and fixed im...
Balz Zimmermann-Strasse 7
Founded in 1981
Key Executives for Nobel Biocare Holding AG
Chief Executive Officer
Total Annual Compensation: $2.0M
Compensation as of Fiscal Year 2013.
Nobel Biocare Holding AG Key Developments
Nobel Biocare Unveils New Cement-Free Solution for Molar Teeth Restoration
Mar 17 15
Nobel Biocare Holding AG has unveiled a new complete, cement-free posterior treatment solution developed for restoration of molar teeth. The solution features a choice of new wide-platform implants and restorative options designed specifically for the posterior region. Also being launched at IDS is an entire new parallel-walled implant system, NobelParallel Conical Connection (CC). Nobel Biocare's new complete posterior solution incorporates new 5.5 mm wide-platform (WP) implant options. Clinicians can choose from the NobelParallel CC WP and new NobelActive WP, both designed for optimized emergence profiles for large molar crowns.
Nobel Biocare Holding AG to Report Fiscal Year 2014 Final Results on Apr 28, 2015
Feb 16 15
Nobel Biocare Holding AG announced that they will report fiscal year 2014 final results on Apr 28, 2015
Nobel Biocare Announces Management Changes
Jan 7 15
Nobel Biocare announced that effective February 1, 2015, Mr. Tullio Di Dio will be appointed Chief Financial Officer of Nobel Biocare succeeding Mr. Oliver Walker as he has decided to leave the company to pursue his career interests outside Nobel Biocare. Mr. Di Dio joins Nobel Biocare with 23 years of finance experience including assignments at United Technologies, Roche and during the past 12 years with Danaher. Most recently, Mr. Di Dio served as Vice President, Finance for Beckman Coulter EMEA. He played an important role in integrating Beckman Coulter into Danaher.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 9, 2015
September 15, 2014
Most Searched Private Companies
Sponsored Financial Commentaries